Lindis Biotech GmbH
LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting
DGAP-News: Lindis Biotech GmbH
/ Key word(s): Conference/Study
LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting Martinsried, Germany, June 1, 2022 – LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, announces the online publication of an abstract presenting interim data from the Company’s Catunibla Phase I dose escalation trial with CATUMAXOMAB at the American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract is available at: https://meetings.asco.org/abstracts-presentations/209733/video. The data showed that all patients in the higher dose group (70 μg) achieved a complete remission as best response following first TUR-B and CATUMAXOMAB treatment alone with no recurrence over length of follow-up (1 year). Remarkably, carcinomas in situ observed at first TUR-B were no longer detectable in three of five patients following CATUMAXOMAB treatment. The strong reduction of urinary EpCAM positive cells during and after CATUMAXOMAB treatment, suggests that the trifunctional bispecific EpCAM targeting antibody binds and efficiently kills EpCAM-positive bladder cancer cells in urine milieu. It shows considerable potential to extend the tumor-free period within treatments in these patients and consequently significantly reduce the number of BCG instillations required, the current standard therapy with well-known severe side effects. CATUMAXOMAB was well tolerated, and there was no dose limiting toxicity. No instillation-related reactions were observed and proinflammatory cytokines typically remained below lower limit of quantification (LLQ). Due to the specific anatomy of the bladder and direct administration of the treatment via urinary catheter, CATUMAXOMAB was not detectable in the systemic circulation. Human anti-mouse-antibodies (HAMA) responses were weak, transient in nature and not associated with any adverse events Dr. med. Felix Albert, Senior Physician at Urological Clinic Munich-Planegg where the trial is conducted and first author, said. “The achievement of complete remissions following CATUMAXOMAB treatment, as demonstrated in the first two dose cohorts, strengthens the evidence of the therapy’s potential. We were especially pleased to see that the in Situ carcinomas identified during first TUR-B were no longer detected in a follow-up resection in three patients after treatment with CATUMAXOMAB. Due to their diffuse location in the tissue, these types of tumors cannot be surgically removed, and usually require instillation therapy with BCG with all its well-known adverse side effects. This treatment was safe and easy to administer, and these initial results solidify our belief, that CATUMAXOMAB could significantly improve clinical outcomes for patients with NMIBC who have limited treatment options.” Dr. Horst Lindhofer, founder, and CEO of LINDIS Biotech and inventor of CATUMAXOMAB, commented: “We are pleased with the inclusion of our clinical data in such a high-profile conference. The observed clinical activity and safety is highly encouraging and underscores the earlier results with long lasting remissions we have seen on a named-patient basis. I very much look forward to sharing the complete data set of the dose escalation Phase I Catunibla trial at further scientific conferences.” Abstract information More Information: About Catunibla About LINDIS Biotech GmbH For more information please contact: LINDIS Biotech GmbH MEDIENANFRAGEN
01.06.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Lindis Biotech GmbH |
Am Klopferspitz 19 | |
82152 Martinsried | |
Germany | |
Phone: | +4989200066440 |
E-mail: | info@lindisbiotech.de |
Internet: | https://www.lindisbiotech.com/ |
EQS News ID: | 1364071 |
End of News | DGAP News Service |